Barbara Marsh, MD
Ophthalmology · Albuquerque, NMNPI 1194726240
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $500 of the $797 with a category attached, or 62.7%. AbbVie accounts for 91.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $539 and has fallen 81.4% since, to $100 in 2025. That places this record below the midpoint for ophthalmology clinicians in NM, where the typical reported total is $868.
Across 19 payments — averaging $41.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$727
- Glaukos Corporation$30
- Amgen$22
- Bausch & Lomb Americas Inc.$18
Across 44 payments — averaging $1192.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$52K
What the payments were for
- Consulting fees$50063%
- Food & beverage$29737%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 15 | $727 |
| Glaukos Corporation | 2 | $30 |
| Amgen | 1 | $22 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN$500
How this compares
$797 in reported general payments places this provider in the 40th percentile of 81 ophthalmology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 985 | $492,778 |
| RhopressaNetarsudil Mesylate | 108 | $61,047 |
| Latanoprost | 3,470 | $60,185 |
| CombiganBrimonidine Tartrate/Timolol | 140 | $58,009 |
| Travoprost | 311 | $47,605 |
| Alphagan PBrimonidine Tartrate | 132 | $45,468 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 201 | $37,384 |
| RestasisCyclosporine | 26 | $30,700 |
| Brimonidine Tartrate | 690 | $25,266 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,300 | $23,606 |
| VyzultaLatanoprostene Bunod | 35 | $19,826 |
| Prednisolone Acetate | 365 | $15,182 |
| Timolol Maleate | 1,007 | $11,641 |
| Dorzolamide Hcl | 491 | $10,720 |
| Brinzolamide | 44 | $9,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $727 | $626,9551,283 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $18 | $19,82635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 81 ophthalmology providers in New Mexico.
Other ophthalmology in Albuquerque
- Robert MelendezAlbuquerque$349K
- John PitcherAlbuquerque$307K
- Christopher RoybalAlbuquerque$51K
- Stephen ColemanAlbuquerque$12K
- Rachel DavisAlbuquerque$10K
- Ian ThompsonAlbuquerque$10K
- Paul SanchezAlbuquerque$8K
- Iuri GolubevAlbuquerque$7K
- Thomas GilletteAlbuquerque$6K
- Kenneth DownesAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.